TMC-310911(也称ASC-09)是一种最初被研究用于治疗HIV/AIDS的抗病毒药物。它是一种蛋白酶抑制剂,与达芦那韦有关。[1][2]尽管TMC-310911在开发后,其最终用途不是用于治疗艾滋病,但对于其它病毒性疾病的治疗研究仍在进行。它在2020年3月进入了COVID-19治疗的临床试验阶段。[3][4]
Quick Facts 法律规范状态, 法律规范 ...
TMC-310911 |
|
法律规范 |
|
---|
|
[(3As,4R,6aR)-2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan-4-yl] N-[(2S,3R)-4-[[2-[(1-cyclopentylpiperidin-4-yl)amino]-1,3-benzothiazol-6-yl]sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate
|
CAS号 | 1000287-05-7 Y |
---|
PubChem CID | |
---|
DrugBank | |
---|
ChemSpider | |
---|
UNII | |
---|
|
化学式 | C38H53N5O7S2 |
---|
摩尔质量 | 755.99 |
---|
3D模型(JSmol) | |
---|
CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CO[C@@H]3[C@H]2CCO3)O)S(=O)(=O)C4=CC5=C(C=C4)N=C(S5)NC6CCN(CC6)C7CCCC7
|
InChI=1S/C38H53N5O7S2/c1-25(2)22-43(23-33(44)32(20-26-8-4-3-5-9-26)41-38(45)50-34-24-49-36-30(34)16-19-48-36)52(46,47)29-12-13-31-35(21-29)51-37(40-31)39-27-14-17-42(18-15-27)28-10-6-7-11-28/h3-5,8-9,12-13,21,25,27-28,30,32-34,36,44H,6-7,10-11,14-20,22-24H2,1-2H3,(H,39,40)(H,41,45)/t30-,32-,33+,34-,36+/m0/s1 Key:JQUNFHFWXCXPRK-AMMMHQJVSA-N
|
Close
Dierynck I, Van Marck H, Van Ginderen M, Jonckers TH, Nalam MN, Schiffer CA, Raoof A, Kraus G, Picchio G. TMC310911, a novel human immunodeficiency virus type 1 protease inhibitor, shows in vitro an improved resistance profile and higher genetic barrier to resistance compared with current protease inhibitors. Antimicrobial Agents and Chemotherapy. December 2011, 55 (12): 5723–31. PMC 3232804 . PMID 21896904. doi:10.1128/AAC.00748-11.
Catapang JK, Billones JB. On the Generation of Novel Ligands for SARS-CoV-2 Protease and ACE2 Receptor via Constrained Graph Variational Autoencoders. ChemRxiv. March 2020. doi:10.26434/chemrxiv.12011157.v3.